Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Heart implant brings hope to refractory angina patients

The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...

Researchers genetically engineer snake antivenom

An international team of researchers has used genetic engineering to create so-called...

Common medications linked to adverse breast cancer outcomes

An international study has found concerning evidence about the impact of a range of common...

Content from other channels on our network

The environmental impact of AI: a help or hindrance for industry?

The return of domestic solar manufacturing to Australia

S&P Global reports manufacturing sector’s return to expansion

Siemens showcases AI that autonomously executes engineering tasks

Advantech partners with D3 Embedded on AMR sensing and computing

Managing Aging Water Infrastructure: A Proactive Approach

Researchers to supercharge Australia's grid resilience

Epson celebrates a 50-year legacy with progress in sustainable innovation

Condensate and Cooling Water Monitoring and Aromatics Detection

Agreement unites clean energy providers

Slowing the ripening process to improve post-harvest quality

Handmade Food + High-Growth Systems: How Fishbowl scaled up Adelia's Operations

The Arnott's Group appoints its Chief People Officer

PEAL Is Here: Why Front-End Allergen Control Matters More Than Ever

Pure Foods Tasmania adds dairy to its ice cream portfolio